Document
IPR2022-00855, No. 1011 Exhibit - Riddell (P.T.A.B. Apr. 12, 2022)
Cite Document
IPR2022-00855, No. 1011 Exhibit - Riddell (P.T.A.B. Apr. 12, 2022)
+ More Snippets
Document
IPR2022-00855, No. 1001 Exhibit - 9,540,445 Patent (P.T.A.B. Apr. 12, 2022)
Cite Document
IPR2022-00855, No. 1001 Exhibit - 9,540,445 Patent (P.T.A.B. Apr. 12, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2044 Exhibit - Adam Bagg Aff, July 19, 2022 (P.T.A.B. Jul. 19, 2022)
Cite Document
IPR2022-00855, No. 2044 Exhibit - Adam Bagg Aff, July 19, 2022 (P.T.A.B. Jul. 19, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2039 Exhibit - Cor HJ Lamers et al, Treatment of Metastatic Renal Cell Carcinoma With Autologous T Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX Fi...
Cite Document
IPR2022-00855, No. 2039 Exhibit - Cor HJ Lamers et al, Treatment of Metastatic Renal Cell Carcinoma With Autologous T Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX First Clinical Ex
+ More Snippets
Document
IPR2022-00855, No. 1012 Exhibit - Porter (P.T.A.B. Apr. 12, 2022)
Cite Document
IPR2022-00855, No. 1012 Exhibit - Porter (P.T.A.B. Apr. 12, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2054 Exhibit - EX 2054 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2054 Exhibit - EX 2054 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2062 Exhibit - EX 2062 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2062 Exhibit - EX 2062 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2048 Exhibit - EX 2048 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2048 Exhibit - EX 2048 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2059 Exhibit - EX 2059 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2059 Exhibit - EX 2059 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2079 Exhibit - EX 2079 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2079 Exhibit - EX 2079 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2072 Exhibit - EX 2072 (P.T.A.B. Feb. 13, 2023)
Cite Document
IPR2022-00855, No. 2072 Exhibit - EX 2072 (P.T.A.B. Feb. 13, 2023)
+ More Snippets
Document
IPR2022-00855, No. 2006 Exhibit - Denise Grady, FDA Approves First Gene Altering Leukemia Treatment, Costing $475,000, NY TIMES Aug 30, 2017, httpswwwnytimescom20170830healthgen...
Cite Document
IPR2022-00855, No. 2006 Exhibit - Denise Grady, FDA Approves First Gene Altering Leukemia Treatment, Costing $475,000, NY TIMES Aug 30, 2017, httpswwwnytimescom20170830healthgene therapy cancerhtml (P
+ More Snippets
Document
IPR2022-00855, No. 2010 Exhibit - Barbara Savoldo et al, CD28 costimulation improves expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients, 121 J CLIN...
Cite Document
IPR2022-00855, No. 2010 Exhibit - Barbara Savoldo et al, CD28 costimulation improves expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients, 121 J CLINICAL INVEST
+ More Snippets
Document
IPR2022-00855, No. 2027 Exhibit - Supplemental Information Disclosure Statement Initialed by Examiner Apr 18, 2016, US Patent Application No 14,997,136 (P.T.A.B. Jul. 19, 2022)
Cite Document
IPR2022-00855, No. 2027 Exhibit - Supplemental Information Disclosure Statement Initialed by Examiner Apr 18, 2016, US Patent Application No 14,997,136 (P.T.A.B. Jul. 19, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2029 Exhibit - Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma CART 19, CLINICALTRIALSGOV April 29, 2009, httpweba...
Cite Document
IPR2022-00855, No. 2029 Exhibit - Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma CART 19, CLINICALTRIALSGOV April 29, 2009, httpwebarchiveorgweb200909030
+ More Snippets